Obermatt
See Similar Stocks →

ScinoPharm

TAI:1789 · TW0001789006
PharmaceuticalsSmall

360

25
Medium confidence — indicative
EV / EBIT18
Price / Owner Earnings8
Owner Earnings Yield53
Dividend Yield1
Price/Sales9
EV / Gross Profit11
Price/Book39
Return on Capital43
Cash Return on Capital52
Return on Equity45
EBIT Margin31
Gross Profitability17
Cash Conversion93
Accruals69
Owner Earnings Margin74
Sales growth32
Profit Growth17
Long-Term EPS Growth21
Owner Earnings Growth40
Reinvestment92
Price momentum85
Debt load81
Refinancing26
Debt Payback100
Liquidity58
Analyst ratings12
Expectations trend50
Market mood59
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

ScinoPharm clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryTaiwan
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeTWSE
Founded1997
Employees104
Websitescinopharm.com.tw
ISINTW0001789006
Last UpdateApr 2, 2026
Index & Theme
CardiovascularOsteoporosisManufacturingPharmaceutical

Description

Analysis

Hope premium

ScinoPharm Taiwan, Ltd. carries what we call a hope premium: an average business trading at an ambitious price.

The price is expensive. You pay 45.3× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone.

The trajectory is moderate and the balance sheet is sturdy. The company scores 8/20 on our value-creation score: creating some value. Analyst sentiment is cautious.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
15
2023202420252026

All-time high

39

Jan 2023

All-time low

1

Mar 2026

Average rank

20

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
9
16
13
26
Price/Earnings
1
12
7
36
Price/Book
39
35
41
65
Dividend Yield
1
36
49
53
Value (overall)
4
18
24
41

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare ScinoPharm with its peers
Chunghwa Chemical Synthesis & Biotech
TAI:1762
13
CountryTaiwan
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Bora Pharmaceuticals
TAI:6472
27
CountryTaiwan
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
ST Pharm
KOE:237690
86
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Panion & Bf Biotech
TAI:1760
84
CountryTaiwan
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
JW Pharmaceutical
KSC:001060
95
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Kukje Pharma
KSC:002720
43
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →